Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Jun;51(6):758–760. doi: 10.1136/ard.51.6.758

Double blind, placebo controlled study of metronidazole as a disease modifying agent in the treatment of rheumatoid arthritis.

D A Marshall 1, J A Hunter 1, H A Capell 1
PMCID: PMC1004741  PMID: 1616359

Abstract

Anecdotal reports suggest that metronidazole may have disease modifying activity in the treatment of rheumatoid arthritis. To assess possible beneficial effects a double blind, comparative trial of metronidazole and placebo was performed. Fifty patients with active rheumatoid arthritis were randomly allocated to receive active drug (n = 24) or placebo (n = 26) and reviewed at weeks 0, 1, 4, 8, 12, 16, and 24. Detailed assessment of drug safety, biochemical and haematological parameters, and efficacy was made at these dates. Dose regimen was 400 mg twice daily from weeks 0 to eight, increasing to 400 mg three times a day from weeks nine to 24 provided that no adverse effects were recorded. Most patients were unable to tolerate metronidazole because of side effects or lack of efficacy, with only five (21%) continuing to take the drug at 24 weeks. For those patients attaining 12 weeks of treatment an overall improvement in articular index and morning stiffness was found. No improvement in laboratory indices of disease activity was seen, however. In this study metronidazole did not have disease modifying properties and was unacceptably toxic.

Full text

PDF
758

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duffy L. F., Daum F., Fisher S. E., Selman J., Vishnubhakat S. M., Aiges H. W., Markowitz J. F., Silverberg M. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology. 1985 Mar;88(3):681–684. doi: 10.1016/0016-5085(85)90137-4. [DOI] [PubMed] [Google Scholar]
  2. El-Ghobarey A. F., Mavrikakis M. E., Macleod M., Reynolds P. M., Capell H. A., Spencer D. G., Balint G., Mathieu J. P., McAllister T., Cooney A. Clinical and laboratory studies of levamisole in patients with rheumatoid arthritis. Q J Med. 1978 Jul;47(187):385–400. [PubMed] [Google Scholar]
  3. Harkness J. A., Griffin A. J., Heinrich I., Gibson T., Grahame R. A double-blind comparative study of metronidazole and placebo in rheumatoid arthritis. Rheumatol Rehabil. 1982 Nov;21(4):231–234. doi: 10.1093/rheumatology/21.4.231. [DOI] [PubMed] [Google Scholar]
  4. Pybus P. K. Metronidazole in rheumatoid arthritis. S Afr Med J. 1984 Mar 24;65(12):454–454. [PubMed] [Google Scholar]
  5. Pybus P. K. Metronidazole in rheumatoid arthritis. S Afr Med J. 1985 Jun 29;67(26):1039–1040. [PubMed] [Google Scholar]
  6. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES